Product was BioRestorative Therapies’s largest product and service line in fiscal 2025, bringing in $300.00K of $359.70K (83%).
| Product and Service | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|
| Product | — | $300.00K | $300.00K |
| Royalty | $145.80K | $101.00K | $59.70K |
| Total | $145.80K | $401.00K | $359.70K |
BioRestorative Therapies brought in $359.70K from its two product and service lines in fiscal 2025, the year ended December 31, 2025. That was down 10.3% from $401.00K in fiscal 2024. Product was the largest at $300.00K (83.4%), ahead of Royalty at $59.70K (16.6%).
Compared with fiscal 2024, Product grew 0.0% to $300.00K, while Royalty fell 40.9% to $59.70K.
BioRestorative Therapies began breaking out Product in fiscal 2024, when it brought in $300.00K.
BioRestorative Therapies (BRTX) reports its revenue by product and service. In fiscal 2025, Product was its largest product and service line, bringing in $300.00K (83.4% of the total), followed by Royalty at $59.70K (16.6%).
Product was BioRestorative Therapies' largest product and service line in fiscal 2025, bringing in $300.00K, or 83.4% of the $359.70K total across its two product and service lines.
Every figure comes from BioRestorative Therapies' annual financial filings, as reported. Each line keeps the name BioRestorative Therapies gives it, and years follow its fiscal calendar.
BioRestorative Therapies' revenue by product and service goes back to fiscal 2023, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.